High disease activity is associated with high disease damage in an Iranian inception cohort of patients with lupus nephritis

Clinical and Experimental Rheumatology

Volumn 31, Issue 1, 2013, Pages 69-75

  Shariati Sarabi, Zhaleh ^a   Monzavi, Seyed Mostafa ^a   Ranjbar, Amin ^a   Esmaily, Habibollah ^b   Etemadrezaie, Hamid ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ECLAM; Lupus nephritis; Medication adherence; SDI; SLEDAI

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; ATTITUDE TO HEALTH; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ETHNIC GROUP; FEMALE; FOLLOW UP; HUMAN; IRAN; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; SEX DIFFERENCE; SLEDAI; SOCIAL STATUS;

ADULT; ANALYSIS OF VARIANCE; BIOPSY; FEMALE; HUMANS; IRAN; KIDNEY; LUPUS NEPHRITIS; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84874828394     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. MANSON JJ, RAHMAN A. Systemic lupus erythematosus. Orphanet J Rare Dis 2006; 1: 6.
2. NAZARINIA MA, GHAFFARPASAND F, SHAMSDIN A, KARIMI AA, ABBASI N, AMIRI A. Systemic lupus erythematosus in the Fars Province of Iran. Lupus 2008; 17: 221-7.
3. AKBARIAN M, FAEZI ST, GHARIBDOOST F et al. Systemic lupus erythematosus in Iran. a study of 2280 patients over 33 years. Int J Rheum Dis 2010; 13: 374-9.
4. GRIFFITHS B, MOSCA M, GORDON C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res ClinRheumatol 2005; 19: 685-708.
5. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
6. VITALI C, BENCIVELLI W, ISENBERG DA et al. Disease activity in systemic lupus erythematosus. report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 527-39.
7. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992; 19: 608-11.
8. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices. international validation. J Rheumatol 1994; 21: 1468-71.
9. VITALI C, BENCIVELLI W, ISENBERG DA et al. Disease activity in systemic lupus erythematosus. report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 541-7.
10. GLADMAN D, GINZLER E, GOLDSMITH C et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum 1996; 39: 363-9.
11. STOLL T, SEIFERT B, ISENBERG DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-54.
12. HOCHBERG MC. Updating the AmericanCollege of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
13. TREHARNE GJ, LYONS AC, HALE ED, DOUGLAS KM, KITAS GD. 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology 2006; 45: 1-5.
14. DE KLERK E. Measurement of patients compliance with drug therapy. an overview. In VINGERHOETS A (Ed.). Assessment in Behavioral Medicine. East Sussex, Routledge 2002: 215-44.
15. GLADMAN DD, IBANEZ D, UROWITZ MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91.
16. BOMBARDIERI S, VITALI C, CAPONI L et al. Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12 (Suppl. 11): S45-8.
17. MOSCA M, TANI C, CARLI L et al. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: S126-9.
18. VITALI C, BENCIVELLI W, MOSCA M et al. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 1999; 26: 498-501.
19. SUTCLIFFE N, CLARKE AE, GORDON C, FAREWELL V, ISENBERG DA. The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus. Rheumatology 1999; 38: 1130-7.
20. KARLSON EW, DALTROY LH, LEW RA et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 47-56.
21. NOSSENT JC. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus. changes in and relationship to disease activity, corticosteroid therapy, and prognosis. J Rheumatol 1998; 25: 654-9.
22. NOSSENT J, KISS E, ROZMAN B et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010; 19: 949-56.
23. GILBOE IM, KVIEN TK, HUSBY G. Disease course in systemic lupus erythematosus. changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28: 266-74.
24. STOLL T, SUTCLIFFE N, MACH J, KLAGHOFER R, ISENBERG DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus-a 5-yr prospective study. Rheumatology 2004; 43: 1039-44.
25. BRUNNER HI, SILVERMAN ED, TO T, BOMBARDIER C, FELDMAN BM. Risk factors for damage in childhood-onset systemic lupus erythematosus. cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-44.
26. SWAAK AJ, VAN DEN BRINK HG, SMEENK RJ et al. Systemic lupus erythematosus. clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology 1999; 38: 953-8.
27. GLADMAN DD, UROWITZ MB, ONG A, GOUGH J, MACKINNON A. Lack of correlation among the 3 outcomes describing SLE. disease activity, damage and quality of life. Clin Exp Rheumatol 1996; 14: 305-8.
28. FREIRE EA, MAIA IO, NEPOMUCENO JC, CICONELLI RM. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in North-eastern Brazil. Clin Rheumatol 2007; 26: 423-8.
29. SARABI ZS, CHANG E, BOBBA R et al. Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. Arthritis Rheum 2005; 53: 609-12.
30. WELLS DK, WARD MM. Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2010; 28: 223-9.
31. FALASCHI F, RAVELLI A, MARTIGNONI A et al. Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1405-9.
32. ZONANA-NACACH A, CAMARGO-CORONEL A, YÁÑEZ P et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus. relationship with disease duration. Lupus 1998; 7: 119-23.
33. IBAÑEZ D, GLADMAN D, UROWITZ M. Summarizing disease features over time. II. Variability measures of SLEDAI-2K. J Rheumatol 2007; 34: 336-40.
34. YEE CS, HUSSEIN H, SKAN J, BOWMAN S, SITUNAYAKE D, GORDON C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology 2003; 42: 276-9.
35. SKARE TL, SCHÖNROCK AC. Clinical profile of patients with lupus nephritis. Reumatismo 2009; 61: 316-7.
36. RAHMAN P, GLADMAN DD, UROWITZ MB, HALLETT D, TAM LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 93-6.
37. GORGOS L, GOLDMAN D, PETRI M. The ACR/SLICC damage index in systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheum 1993; 36 (Suppl. 9): S68.
38. MOK CC, LEE KW, HO CT, LAU CS, WONG RW. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000; 39: 399-406.
39. FORTIN PR, ABRAHAMOWICZ M, NEVILLE C et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 1998; 7: 101-7.
40. GARCIA-GONZALEZ A, RICHARDSON M, GARCIA POPA-LISSEANU M et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin-Rheumatol 2008; 27: 883-9.
41. KONERU S, KOCHARLA L, HIGGINS GC et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol 2008; 14: 195-201.
42. PETRI M, PEREZ-GUTTHANN S, LONGENECKER JC, HOCHBERG M. Morbidity of systemic lupus erythematosus. role of race and socioeconomic status. Am J Med 1991; 91: 345-53.
43. BRUCE IN, GLADMAN DD, UROWITZ MB. Factors associated with refractory renal disease in patients with systemic lupus erythematosus. the role of patient nonadherence. Arthritis Care Res 2000; 13: 406-8.
44. ADLER M, CHAMBERS S, EDWARDS C, NEILD G, ISENBERG D. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology 2006; 45: 1144-7.